Keene, BW, Atkins, CE, Bonagura, JD, et al. ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs. J Vet Intern Med. 2019; 33: 1127– 1140.
Fuentes VL, ed. BSAVA Manual of Canine and Feline Cardiorespiratory Medicine. 2. ed. Quedgeley: 2. BSAVA; 2010.
Ljungvall I, Rishniw M, Porciello F, et al. Murmur intensity in small-breed dogs with myxomatous mitral valve disease reflects disease severity. J Small Anim Pract. 2014;55(11):545-550.
Boswood A, Häggström J, Gordon SG, et al. Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study—A Randomized Clinical Trial. J Vet Intern Med. 2016;30(6):1765-1779.
Cornell C, Kittleson M, Della Torre P, et al. Allometric scaling of M-mode cardiac measurements in normal adult dogs. J Vet Intern Med. 2004;18(3):311-321.
Häggström J, Boswood A, O’Grady M, et al. Effect of pimobendan or benazepril on survival times of dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study. J Vet Intern Med. 2008;22:1124–1135.
McCauley SR, Clark SD, Quest BW, et al. Review of canine dilated cardiomyopathy in the wake of diet-associated concerns. J Anim Sci. 2020;98(6):skaa155.
Wess G, Domenech O, Dukes-McEwan J, et al. European Society of Veterinary Cardiology screening guidelines for dilated cardiomyopathy in Doberman Pinschers. J Vet Cardiol. 2017;19(5):405–415.
Wess G, Schulze A, Butz V, et al. Prevalence of dilated cardiomyopathy in Doberman Pinschers in various age groups. J Vet Intern Med. 010;24(3):533-538.
Cornell CC, Kittleson MD, Della Torre P, et al. Allometric scaling of M-mode cardiac measurements in normal adult dogs. J Vet Intern Med. 2004;18(3):311-321.
Summerfield NJ, Boswood A, O’Grady MR, et al. Efficacy of pimobendan in the prevention of congestive heart failure or sudden death in Doberman Pinschers with preclinical dilated cardiomyopathy (The PROTECT Study). J Vet Intern Med. 2012;26(6):1337–1349.
O’Grady MR, O’Sullivan ML, Minors SL, et al. Efficacy of benazepril hydrochloride to delay the progression of occult dilated cardiomyopathy in Doberman Pinschers. J Vet Intern Med. 2009;23(5):977–983.
Vetmedin® Chew 1.25 mg, 5 mg and 10 mg chewable tablets for dogs. Active substance: Pimobendan. Uses: For the treatment of canine congestive heart failure originating from dilated cardiomyopathy or valvular insufficiency (mitral and/or tricuspid valve regurgitation). (See also section 4.9 of the SPC). For the treatment of dilated cardiomyopathy in the preclinical stage (asymptomatic with an increase in left ventricular end-systolic and end-diastolic diameter) in Doberman Pinschers following echocardiographic diagnosis of cardiac disease (see sections 4.4 and 4.5 of the SPC). For the treatment of dogs with myxomatous mitral valve disease (MMVD) in the preclinical stage (asymptomatic with a systolic mitral murmur and evidence of increased heart size) to delay the onset of clinical symptoms of heart failure (see sections 4.4 and 4.5 of the SPC). UK: POM-V IE: POM. For information about side effects, precautions, warnings and contraindications please refer to the product packaging and package leaflet. Further information available in the SPC or from Boehringer Ingelheim Animal Health UK Ltd., RG12 8YS, UK. UK Tel: 01344 746959 (sales) or 01344 746957 (technical), IE Tel: 01 291 3985 (all queries).
Email: vetenquiries@boehringer-ingelheim.com. Vetmedin® is a registered trademark of Boehringer Ingelheim Vetmedica GmbH, used under licence. ©2022 Boehringer Ingelheim Animal Health UK Ltd. All rights reserved. Date of preparation: June 2022. UI-CAN-0166-2021. Use Medicines Responsibly.